Tag: Biotech and Pharma

Pfizer on Tuesday reported third-quarter results that topped estimates and hiked its full-year outlook, as demand for its newly launched and acquired products grows.

AstraZeneca, opens new tab on Friday unveiled a restructuring ‌programme aimed at funding investment in its drug pipeline, but gave few details on how it would achieve expected annual savings of about $1.5 billion.

Merck delivered a clean beat-and-raise third quarter, but strong near-term numbers may matter little to investors fixated on the drugmaker’s post-2028 pipeline.

Eli Lilly on Thursday reported third-quarter earnings and revenue that blew past estimates and hiked its full-year sales outlook, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soared again.

Revenue rose 11% to $2.8 billion, beating forecasts of $2.6 billion, fueled by strength in Biogen’s growth portfolio and the first full quarter of contributions from its acquisition of Apellis Pharmaceuticals in May.

Moderna shares dropped as much as 25% on Thursday following the leak of partial data on its closely watched cancer vaccine developed with Merck.

Oracle and AstraZeneca announced a non-binding agreement to explore how AI and real-world data can be used to identify eligible patients for clinical trials, accelerate evidence generation, and bring research insights into clinical care workflows, according to a press release issued Oct. 20, 2026.

The EMA’s advisory committee recommended approving Foundayo for adults with obesity or those who are overweight and have related health conditions.

Hong Kong-listed Metis TechBio said on Monday it has entered ​into a collaboration agreement with Eli ‌Lilly worth up to $1.1 billion to research and develop tissue-specific drug delivery technologies.

Roche said on Monday ​it will present ‌new late-stage trial results at the ​ESMO 2026 ​cancer meeting in Madrid, ⁠including data ​showing its lung ​cancer drug divarasib worked better than current KRAS ​G12C treatments.

Adjusted earnings per share of $2.59 beat the consensus estimate of $2.53 by $0.06. Revenue reached $25.4 billion, slightly above the $25.38 billion consensus, representing a 5.9% increase from $24.0 billion in the same quarter last year.

Bristol Myers Squibb shares surged 6.5% on Monday following the announcement of positive top-line results from two separate Phase 3 clinical trials evaluating targeted therapies for neuroendocrine tumors and idiopathic pulmonary fibrosis.

Sanofi and Regeneron announced Thursday an expansion of their immunology drug alliance, under which Regeneron will receive $1 billion upfront and be eligible for up to $7 billion in additional milestone payments.

Ξεκίνησε τις πωλήσεις του Durogesic στη γαλλική αγορά η Lavipharm.

Shares in Swedish microcap stock Nanexa more than doubled early Friday after the drug-delivery group revealed a $1.33 billion licensing deal with pharma giant Novo Nordisk.

AbbVie and Iambic Therapeutics announced a multi-year collaboration to apply Iambic’s artificial intelligence platform to small molecule drug discovery 

Novo Nordisk said on Monday its ​next-generation experimental drug, CagriSema, delivered an ‌estimated average weight loss of 12.4% in a late-stage trial in patients with diabetes, outperforming ​Eli Lilly’s rival drug.

Novo set out its 2030 strategic ambitions at a Capital Markets Day in London on Monday, but the plan failed to satisfy investors hoping for a more decisive turnaround.

Xenon Pharmaceuticals said it submitted a regulatory filing for its lead drug candidate that puts it on the brink of its first commercial product.

Σημαντική αύξηση των ενοποιημένων πωλήσεων προ claw back και rebate κατά 24,1% το α’ εξάμηνο κατέγραψε ο όμιλος Lavipharm ενώ τα κέρδη EBITDA από συνεχιζόμενες δραστηριότητες αυξήθηκαν κατά 5,2%.